AstraZeneca (AZN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.
Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Country | GB |
IPO Date | May 12, 1993 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 89,900 |
CEO | Pascal Soriot D.V.M., M.B.A. |
Contact Details
Address: 1 Francis Crick Avenue Cambridge, GB | |
Website | https://www.astrazeneca.com |
Stock Details
Ticker Symbol | AZN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000901832 |
CUSIP Number | 046353108 |
ISIN Number | US0463531089 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Pascal Soriot D.V.M., M.B.A. | Chief Executive Officer & Executive Director |
Dr. Aradhana Sarin M.D. | Chief Financial Officer & Executive Director |
Andrew P. Barnett | Head of Investor Relations |
David Fredrickson | Executive Vice-President of Oncology Business Unit |
Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development |
Gonzalo Vina | Head of Global Media Relations |
Iskra Reic | Executive Vice President of International |
Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
Pam P. Cheng | EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 21, 2025 | F-6 | Filing |
Jan 21, 2025 | 6-K | Filing |
Jan 17, 2025 | 6-K | Filing |
Jan 02, 2025 | 6-K | Filing |
Dec 26, 2024 | 6-K | Filing |
Dec 23, 2024 | 6-K | Filing |
Dec 16, 2024 | 6-K | Filing |
Dec 05, 2024 | 6-K | Filing |
Dec 04, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |